India has marked a historic milestone in the field of medical science with the launch of its first indigenously developed CAR T-cell therapy for cancer treatment. President Droupadi Murmu aptly hailed this achievement as a “major breakthrough” that not only signifies progress in medical science but also embodies the spirit of ‘Make in India’. This development, a collaborative effort between the IIT Mumbai and the Tata Memorial Centre, holds immense promise in transforming cancer care not only in India but also globally. CAR T-cell therapy represents a paradigm shift in cancer treatment, offering new hope for patients battling various forms of the disease. The therapy involves genetically modifying a patient’s immune cells to recognize and destroy cancer cells effectively. While this treatment has been available outside India, its prohibitive costs have rendered it inaccessible to the majority. However, the launch of NexCAR19 at a fraction of the international price signifies a significant step towards making advanced cancer care affordable and accessible to all.
The significance of this achievement goes beyond its economic implications. It underscores the prowess of Indian scientists and physicians, highlighting their capability to innovate and develop cutting-edge medical solutions domestically. The success of NexCAR19 not only validates India’s scientific prowess but also positions the country as a formidable player in the global arena of cell and gene therapy. The accessibility of low-cost CAR T-cell therapy holds profound implications for cancer patients in India. With NexCAR19, the landscape of cancer care in India is poised to undergo a transformative change, offering renewed hope and relief to countless patients and their loved ones.
Follow our WhatsApp channel
